<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In this study, we examined the role of Fas-signaling in the apoptotic pathway in <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Ficoll-separated mononuclear cells from 18 bone marrow aspirate specimens obtained from 17 MDS patients, 4 <z:mpath ids='MPATH_458'>normal</z:mpath> healthy donors, and 3 <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> patients transformed from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) were studied for <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression of Fas-L, Fas, and the effectors of their signaling, Caspase 1 and Caspase 3, using reverse transcriptase polymerase chain reaction </plain></SENT>
<SENT sid="2" pm="."><plain>Fas-L, Fas, and Caspase 1 were detectable in <z:hpo ids='HP_0000001'>all</z:hpo> of the samples in the three groups </plain></SENT>
<SENT sid="3" pm="."><plain>Caspase 3 was detectable both in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> specimens but was negligible in <z:mpath ids='MPATH_458'>normal</z:mpath> cells </plain></SENT>
<SENT sid="4" pm="."><plain>The apoptotic index (AI%) determined by in situ end labeling of fragmented DNA in 4-hour cultures of mononuclear cells was significantly higher in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cells compared to <z:mpath ids='MPATH_458'>normal</z:mpath> or t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> cells (mean +/- <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e>: 2.3% +/- 0.4% in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, n = 10 vs. 0.6% +/- 0.2%, n = 4, P = 0.014 in <z:mpath ids='MPATH_458'>normal</z:mpath> cells, and 0.2% +/- 0.2%, n = 3, P = 0.007 in t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> cells) </plain></SENT>
<SENT sid="5" pm="."><plain>Treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cells with anti-Fas-L antibody suppressed <z:mpath ids='MPATH_3'>apoptosis</z:mpath> (AI%: 2.1% +/- 0.6% in untreated vs. 1.37% +/- 0.5% in treated, n = 6, P = 0.02), indicating functional participation of Fas-signaling in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Further, it was found that Fas-L, Fas, and Caspase 1 mRNA expression remained unchanged in 4 hours </plain></SENT>
<SENT sid="7" pm="."><plain>Caspase 3 expression appeared in <z:mpath ids='MPATH_458'>normal</z:mpath> cells after 4 hours and was present at both 0 and 4 hours in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> cells </plain></SENT>
<SENT sid="8" pm="."><plain>In contrast to persistent expression in <z:mpath ids='MPATH_458'>normal</z:mpath> and t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> cells, cells from the 5 MDS patients studied consistently showed significantly lowered or undetectable expression of a negative regulator of Fas, called Fas-associated phosphatase-1 (Fap-1) after 4 hours </plain></SENT>
<SENT sid="9" pm="."><plain>Thus, the high AI% in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> corresponds to a rapid decline in Fap-1 </plain></SENT>
<SENT sid="10" pm="."><plain>Furthermore, in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor alpha (TNF-alpha) treated HL60 promyelocytic cells, a definite periodicity in the expression of different <z:chebi fb="2" ids="33699">mRNAs</z:chebi> was observed with upregulation of TNF-alpha itself at 30 minutes, increased expression of Fas and the appearance of Fas-L after 2 hours, and a decrease in Fap-1 expression after 8 hours </plain></SENT>
<SENT sid="11" pm="."><plain>These results suggest that TNF-alpha not only induces the effectors of Fas-signaling but also may downregulate the inhibitor </plain></SENT>
<SENT sid="12" pm="."><plain>We conclude that a spontaneous and rapid down-regulation of Fap-1, possibly induced by TNF-alpha, a cytokine shown to be present in excess in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> marrows, may underlie the increased apoptotic <z:hpo ids='HP_0011420'>death</z:hpo> of hematopoietic cells in these patients </plain></SENT>
<SENT sid="13" pm="."><plain>Interference with Fap-1 turnover may provide a new therapeutic modality for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>